Sign In
Buy SENS
$5.03
-0.0400 (-0.789%)
At Close: Jul 31, 2026
Senseonics Completes CE Mark Submission for Eversense 365, World's Longest-lasting Continuous Glucose Monitor
04:05pm, Thursday, 06'th Feb 2025
GERMANTOWN, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable c
GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable
Senseonics Holdings (SENS) Reports Q3 Loss, Tops Revenue Estimates
07:41pm, Thursday, 07'th Nov 2024
Senseonics Holdings (SENS) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.04 per share a year ago.
Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript
06:33pm, Thursday, 07'th Nov 2024
Senseonics Holdings, Inc. (NYSE:SENS ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Tim Goodnow - President and Chief Executive Of
Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System
04:30pm, Wednesday, 16'th Oct 2024
Event featuring David T. Ahn, MD from Hoag Medical Group and Jeff Ciaramita, MD from Mercy health system, along with management Event featuring David T. Ahn, MD from Hoag Medical Group and Jeff
Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor
04:10pm, Thursday, 10'th Oct 2024
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older Commercial launch by Ascensia
Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor
04:05pm, Thursday, 10'th Oct 2024
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older
Eversense 365 Launches in the US: One Year. One CGM.
11:00am, Tuesday, 01'st Oct 2024
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, announces that it is launching the Eversense® 365 continuous glucose monitoring (CGM) system, the world's on
Senseonics Stock Down Despite New FDA Approval for Eversense 365
01:18pm, Tuesday, 24'th Sep 2024
SENS' latest regulatory clearance is likely to simplify diabetes management with the help of a long-lasting CGM system.
Eversense 365 Receives FDA Clearance: The World's First One Year CGM
07:00am, Tuesday, 17'th Sep 2024
Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes
Senseonics Holdings, Inc. to Participate in the Upcoming H.C. Wainwright 26th Annual Global Investment Conference
04:05pm, Friday, 06'th Sep 2024
GERMANTOWN, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable
Senseonics Holdings, Inc. Provides Business Update and Full Year 2024 Financial Outlook
04:05pm, Friday, 21'st Jun 2024
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to r
Senseonics Holdings, Inc. to Host Business Update and Analyst Event During the American Diabetes Association's 84th Scientific Sessions
04:05pm, Thursday, 13'th Jun 2024
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos
Senseonics Holdings, Inc. to Participate in the Sidoti Small Cap Conference
04:05pm, Wednesday, 29'th May 2024
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos
